Navigation Links
Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
Date:5/21/2008

rate gluten proteins and have an inflammatory response to the gluten in wheat, barley and rye. This results in varying symptoms such as fatigue, skin rash, anemia, fertility issues, joint pain, weight loss, pale sores inside the mouth, tooth discoloration or loss of enamel, depression, chronic diarrhea or constipation, gas and abdominal pain. The immunology and nutritional abnormalities in celiac disease can potentially result in long-term complications such as osteoporosis, refractory sprue, small intestinal cancer, and lymphoma. The only current treatment for CD is complete elimination of gluten from the diet, which results in remission for most patients, but can be very difficult to implement in practice. "However, the response to the gluten-free diet is poor in up to 30% of patients and dietary nonadherence is the chief cause of persistent or recurrent symptoms."(3)

About "Larazotide Acetate"

Larazotide acetate is an experimental medicine and an inhibitor of barrier dysfunction that has been shown to block abnormally increased intestinal permeability and the genesis of some autoimmune diseases, either as a result of reduction of antigen presentation to the body's immune system, or through inhibitory, direct effects on gastrointestinal associated lymphoid tissue. Larazotide acetate is a non-absorbed peptide which improves mucosal barrier function by inhibiting cytoskeletal reorganization and tight junction disassembly. Larazotide acetate is orally formulated, has been granted "Fast Track" designation by the U.S. Food and Drug Administration for the treatment of celiac disease, and is also being evaluated for the treatment of Crohn's Disease. Results of the Company's first study in celiac patients are available online at: http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2036.2007.03413.x

About Alba

Alba Therapeutics Corporation i
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
2. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
3. PacificGMP Completes GMP Product Fill for Trius Therapeutics
4. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
5. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
6. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
7. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
8. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
9. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
10. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
11. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... DALLAS , February 27, 2015 ... Review, H2 2014 market research report to its ... the Corneal Ulcers, therapeutic pipeline. The ... information on the therapeutic development for Corneal Ulcers. ... infections that includes bacterial infections, viral infections & ...
(Date:2/26/2015)... Ind. , Feb. 26, 2015  Mobility Ventures ... an agreement with Bank of America (NYSE: ... nationwide to receive financing of the revolutionary MV-1 - ... designed from the ground up to provide safe and ... applicants can use their loan to purchase a new ...
(Date:2/26/2015)... DUBLIN , Feb. 26, 2015 Research and ... addition of the "Radiation Therapy Equipment - Global ... This report analyzes the worldwide markets for ... Product Segments: Linear Accelerator, Treatment Planning Systems, and Radiation ... the US, Canada , ...
Breaking Medicine Technology:Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 2Mobility Ventures and Bank of America Announce New Agreement to Simplify Retail Consumer Financing for MV-1 Universally Accessible Vehicle 3Radiation Therapy Equipment - Global Strategic Business Report 2015-2020: Linear Accelerator, Treatment Planning Systems, and Radiation Therapy Simulator 2
... Md., Nov. 4, 2011 The U.S. Food and ... to reduce the risk of stroke in people who ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... and is one of the most common types of ...
... A unique treatment involving the use of hot chemotherapy ... Center. SJH&MC is the first hospital in Southeast Michigan ... offer the treatment. Know as Hyperthermic Intraperitoneal ... number of advanced cancers that have spread to the ...
Cached Medicine Technology:FDA Approves Xarelto to Prevent Stroke in People With Common Type of Abnormal Heart Rhythm 2FDA Approves Xarelto to Prevent Stroke in People With Common Type of Abnormal Heart Rhythm 3St. John Hospital 1st in Region to Offer Innovative Chemotherapy Delivery System 2
(Date:2/27/2015)... USA (PRWEB) February 27, 2015 The ... step program style treatment argue that those who are ... for substance abusers of narcotics and alcohol are enabling ... proven that methadone and suboxone, which are synthetic opiate ... lives and prevent drug addicts from overdosing. These synthetic ...
(Date:2/27/2015)... February 27, 2015 Burien Nursing ... American Health Care, Inc. with the Facility of ... in four key areas: Outstanding quality of care / ... Administrator Lynda Baldwin was invited to attend the awards ... 2015. “I am delighted to receive this award on ...
(Date:2/27/2015)... With Spring’s wet weather on the way, it is ... spaces in mind. The latest article from Clean ... crawl space conditions and repairs. , Clean Crawls begins ... confused as to how water is getting into their crawl ... ways is through cracks in the foundation, walls, ceiling, or ...
(Date:2/27/2015)... Many mattresses contain flame-retardant chemicals ... has introduced organic cotton mattresses and other bedding ... chemicals. Dr. Mercola’s Healthy Home mattresses provide fire ... Organic cotton is significantly less flammable by nature. ... are made by Naturepedic and are certified organic ...
(Date:2/27/2015)... The Hermitage has responded to a Vermont ... date back to 2012. The mitigation work that was ... it was approved in the summer of 2013. ... we agreed to 100% mitigation at our expense," said ... , Barnes further added, "we were surprised and disappointed ...
Breaking Medicine News(10 mins):Health News:America’s Stigma Around Methadone Puts Drug Addicts at an Increased Risk for Fatal Overdose 2Health News:America’s Stigma Around Methadone Puts Drug Addicts at an Increased Risk for Fatal Overdose 3Health News:Burien Nursing and Rehabilitation Center Receives Top Honors with Facility of the Year Award 2Health News:Burien Nursing and Rehabilitation Center Receives Top Honors with Facility of the Year Award 3Health News:Crawl Space FAQs are Answered in Clean Crawls Latest Article 2Health News:Southern Vermont's Hermitage Club Announces Statement Regarding Vermont Attorney General Lawsuit for Permit Violations 2
... therapy early may up odds of disease, study shows, ... and type of hormone replacement therapy women take to ... breast cancer risk they face, a new French study ... menopause appears to boost the risk of breast cancer, ...
... , Online Resource Offers Preventive Tips, News ... a new online resource to help them learn about and help control the spread ... The new Web site, www.H1N1inPA.com , was created by ... virus. , , "We expect to see a steady rise ...
... , WHITE PLAINS, N.Y., Sept. 16 As ... of Cepacol(R) Fizzlers(TM), a single symptom sore throat relief product designed ... parents with children aged 5-12 suffering from sore throat pain. ... ) , , According to consumer research, 29 ...
... , NEW YORK, Sept. 16 HMS ... Minnesota Department of Human Services (DHS) to provide additional third-party liability ... liability services to 39 state Medicaid agencies. , , ... activities," said Billi Jo Zielinski, Assistant Commissioner of Health Care. "This ...
... HARRISBURG, Pa., Sept. 16 Capital BlueCross announced ... H1N1 Flu vaccine for fully-insured members and those with individual ... opt to have their coverage customized to include this benefit. ... be available to the public in October. Various clinical vaccine ...
... , , NEW YORK, Sept. 16 ... Trustees, today announced the appointment of Alan Kadish, M.D., as senior ... , PHOTO: http://www.flickr.com/photos/tourocollege/3923514965/ ... institution in the United States. The college was founded by ...
Cached Medicine News:Health News:Timing, Type of HRT May Determine Breast Cancer Risk 2Health News:Timing, Type of HRT May Determine Breast Cancer Risk 3Health News:New Web Site Will Help Pennsylvanians Learn About, Protect Against Novel H1N1 Flu 2Health News:Introducing Sore Throat Relief Parents Trust in a Form that Fizzles! 2Health News:Capital BlueCross to Cover Administration Costs of H1N1 Vaccine for Fully-Insured Groups, Individuals This Flu Season 2Health News:Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer 2Health News:Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer 3Health News:Touro Appoints Alan Kadish, M.D., Senior Provost and Chief Operating Officer 4
... prints labels up to 8.5 ... It is ideal for wide ... chemical drum labels, primary metal ... banner-sized labels and pallet and ...
... Korchek Technologies CareChek Tx, which ... a software device for blood ... match the patient to the ... bedside before administering a transfusion.The ...
... Management system ensures your patients are receiving ... BloodTrack SafeTx uses the AutoPPI™ barcoded wristband ... collection to transfusion. SafeTx checks that the ... need for bedside paperwork and associated transcription ...
... The automated patient ID verification and laboratory ... the identity of the phlebotomist or nurse, the ... request. If proper verification is made, a bar ... the bedside. Its unique design simplifies and eliminates ...
Medicine Products: